SCHEMBL8906962

SCHEMBL8906962

CC(C)(C)C(=O)[C@H](c1ccccc1)N1CC[C@H](F)C1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.44
DPP7 Q9UHL4 5/20 0.44
CYP3A4 P08684 2/20 0.44
HIF1A Q16665 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.41
ALDH1A1 P00352 6/20 0.40
TSHR P16473 4/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.40
DPP8 Q6V1X1 1/20 0.39
RIPK1 Q13546 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8906944 1.00 DPP4 (0.44) DPP4DPP7CYP3A4HIF1AMEN1
SCHEMBL890204 0.84 DPP4 (0.44) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL13154902 0.84 DPP4 (0.44) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL13154957 0.84 DPP4 (0.44) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL12292181 0.84 DPP4 (0.44) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL890201 0.84 DPP4 (0.44) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL12174930 0.84 DPP4 (0.44) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL3728983 0.84 LMNA (0.58) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL12137589 0.84 LMNA (0.58) DPP4DPP7CYP3A4MEN1KMT2A
SCHEMBL622694 0.84 LMNA (0.58) DPP4DPP7CYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752611-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 US disclosed
US-9127021-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2015-09-08 US disclosed
US-8188132-B2 Linked dibenzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20110300104-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-12-08 US disclosed
US-20110250172-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-10-13 US disclosed
US-20110142798-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-06-16 US disclosed
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300104-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 DPP4 606/4885DPP7 560/4885CYP3A4 204/4885
US-20110250172-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 DPP4 606/4885DPP7 560/4885CYP3A4 204/4885
US-20110142798-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 DPP4 606/4885DPP7 560/4885CYP3A4 204/4885
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES EIF2AK2, NSUN2, ZC3HAV1 DPP4 243/4885DPP7 268/4885CYP3A4 138/4885
US-10752611-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L DPP4 362/4885DPP7 668/4885CYP3A4 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.